The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
Open accessAbstract
The hepatocyte growth factor (HGF) and its receptor, the transmembrane tyrosine kinase cMET, promote cell proliferation, survival, motility, and invasion as well as morphogenic changes that stimulate tissue repair and regeneration in normal cells but can be co-opted during tumor growth. MET overexpression, with or without gene amplification, has been reported in a variety of human cancers, including breast, lung, and GI malignancies. Furthermore, high levels of HGF and/or cMET correlate with poor prognosis in several tumor types, including breast, ovarian, cervical, gastric, head and neck, and non–small-cell lung cancers. Gene amplification and protein overexpression of cMET drive resistance to epidermal growth factor receptor family inhibitors, both in preclinical models and in patients. It is increasingly apparent that the HGF-cMET axis signaling network is complex, and rational combinatorial therapy is needed for optimal clinical efficacy. Better understanding of HGF-cMET axis signaling and the mechanism of action of HGF-cMET inhibitors, along with the identification of biomarkers of response and resistance, will lead to more effective targeting of this pathway for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576
Cappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., del Grammastro, M., Sciarrotta, M. G., Buttitta, F., Incarbone, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1635 · Cited by 557
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Invasive growth: a MET-driven genetic programme for cancer and stem cells
Boccaccio, C., & Comoglio, P. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1912 · Cited by 538
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2749 · Cited by 490
Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473
Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 454
A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00567-0 · Cited by 420
FAUSTO, N. (1991) · Hepatology · doi:10.1016/0270-9139(91)90068-7 · Cited by 418
Sequist, L. V., von Pawel, J., Garmey, E. G., Akerley, W. L., Brugger, W., Ferrari, D., Chen, Y., Costa, D. B., Gerber, D. E., Orlov, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0570 · Cited by 378
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 332
A novel germ line juxtamembrane Met mutation in human gastric cancer
Lee, J.-H., Han, S.-U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 329
Met and hepatocyte growth factor/scatter factor expression in human gliomas.
Koochekpour, S., Jeffers, M., Rulong, S., Taylor, G., Klineberg, E. O., Hudson, E. A., Resau, J. H., & Woude, G. F. V. (1997) · PubMed · Cited by 320
HGF/SF‐met signaling in the control of branching morphogenesis and invasion
Zhang, Y., & Vande Woude, G. F. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10358 · Cited by 307
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., & Comoglio, P. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.032 · Cited by 299
Lokker, N. A., Mark, M. R., Luis, E. A., Bennett, G. L., Robbins, K. A., Baker, J. B., & Godowski, P. J. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05315.x · Cited by 296
Lengyel, E., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K., Salanti, G., Richter, T., Knudsen, B., Vande Woude, G. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 273
Seiwert, T. Y., Jagadeeswaran, R., Faoro, L., Janamanchi, V., Nallasura, V., El Dinali, M., Yala, S., Kanteti, R., Cohen, E. E. W., Lingen, M. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2881 · Cited by 269
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
Danilkovitch‐Miagkova, A., & Zbar, B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15418 · Cited by 268
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
Tuck, A. B., Park, M., Sterns, E. E., Boag, A., & Elliott, B. E. (1996) · Europe PMC (PubMed Central) · Cited by 244
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
Danilkovitch-Miagkova, A., & Zbar, B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215418 · Cited by 244
How to make tubes: signaling by the Met receptor tyrosine kinase
Rosário, M. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00104-1 · Cited by 240
Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor
Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D., & Wiesmann, C. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600243 · Cited by 240
Cancer therapy: can the challenge be MET?
Corso, S., Comoglio, P. M., & Giordano, S. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.04.005 · Cited by 238
Structural basis of hepatocyte growth factor/scatter factor and MET signalling
Gherardi, E., Sandin, S., Petoukhov, M. V., Finch, J., Youles, M. E., Öfverstedt, L.-G., Miguel, R. N., Blundell, T. L., Vande Woude, G. F., Skoglund, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509040103 · Cited by 224
Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript
Chan, A. M.-L., Rubin, J. S., Bottaro, D. P., Hirschfield, D. W., Chedid, M., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1720571 · Cited by 218
Qi, J., McTigue, M. A., Rogers, A., Lifshits, E., Christensen, J. G., Jänne, P. A., & Engelman, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1623 · Cited by 216
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
Puri, N., & Salgia, R. (2008) · Journal of Carcinogenesis · doi:10.4103/1477-3163.44372 · Cited by 211
Targeting the HGF/Met signalling pathway in cancer
Cecchi, F., Rabe, D. C., & Bottaro, D. P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.028 · Cited by 209
The Sema domain of Met is necessary for receptor dimerization and activation
Kong-Beltran, M., Stamos, J., & Wickramasinghe, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.013 · Cited by 209
Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer.
Park, W. S., Oh, R. R., Park, J. Y., Lee, S. H., Shin, M. S., Kim, Y. S., Kim, S. Y., Lee, H. K., Kim, P. J., Oh, S. T., et al. (1999) · PubMed · Cited by 207
Ichimura, E., Maeshima, A., Nakajima, T., & Nakamura, T. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb03111.x · Cited by 201
Olivero, M., Rizzo, M., Madeddu, R., Casadio, C., Pennacchietti, S., Nicotra, M., Prat, M., Maggi, G., Arena, N., Natali, P., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.646 · Cited by 199
Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma
Jagadeeswaran, R., Ma, P. C., Seiwert, T. Y., Jagadeeswaran, S., Zumba, O., Nallasura, V., Ahmed, S., Filiberti, R., Paganuzzi, M., Puntoni, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4567 · Cited by 198
Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H., Cancilla, B., Chu, F., Hitchcock-Bryan, S., Sherman, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 197
Yap, T. A., Olmos, D., Brunetto, A. T., Tunariu, N., Barriuso, J., Riisnaes, R., Pope, L., Clark, J., Futreal, A., Germuska, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0367 · Cited by 196
Spigel, D. R., Ervin, T. J., Ramlau, R., Daniel, D. B., Goldschmidt, J. H., Blumenschein, G. R., Krzakowski, M. J., Robinet, G., Clement-Duchene, C., Barlesi, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7505 · Cited by 193
Self-citationSoman, N. R., Correa, P., Ruiz, B. A., & Wogan, G. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4892 · Cited by 190
Aguirre Ghiso, J. A., Alonso, D. F., Farías, E. F., Gomez, D. E., & Bal de Kier Joffè, E. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00507.x · Cited by 185
Gherardi, E., Youles, M. E., Miguel, R. N., Blundell, T. L., Iamele, L., Gough, J., Bandyopadhyay, A., Hartmann, G., & Butler, P. J. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2034936100 · Cited by 182
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Zeng, Z.-S., Weiser, M. R., Kuntz, E., Chen, C.-T., Khan, S. A., Forslund, A., Nash, G. M., Gimbel, M., Yamaguchi, Y., Culliford, A. T., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.049 · Cited by 180
From Tpr-Met to Met, tumorigenesis and tubes
Peschard, P., & Park, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210201 · Cited by 180
Wen, P. Y., Schiff, D., Cloughesy, T. F., Raizer, J. J., Laterra, J., Smitt, M., Wolf, M., Oliner, K. S., Anderson, A., Zhu, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq198 · Cited by 173
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Cepero, V., Sierra, J. R., Corso, S., Ghiso, E., Casorzo, L., Perera, T., Comoglio, P. M., & Giordano, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0436 · Cited by 167
NK4 (HGF‐antagonist/angiogenesis inhibitor) in cancer biology and therapeutics
Matsumoto, K., & Nakamura, T. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01440.x · Cited by 166
Petrelli, A., Circosta, P., Granziero, L., Mazzone, M., Pisacane, A., Fenoglio, S., Comoglio, P. M., & Giordano, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508156103 · Cited by 164
Basile, J., Afkhami, T., & Gutkind, J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.6889-6898.2005 · Cited by 164
Gordon, M. S., Sweeney, C. J., Mendelson, D. S., Eckhardt, S. G., Anderson, A., Beaupre, D. M., Branstetter, D., Burgess, T. L., Coxon, A., Deng, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1365 · Cited by 162
Boccaccio, C., Gaudino, G., Gambarotta, G., Galimi, F., & Comoglio, P. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99953-9 · Cited by 160
Garcia, S., Dalès, J.-P., Charafe‐Jauffret, E., Carpentier-Meunier, S., Andrac, L., Jacquemier, J. D., Andonian, C., Lavaut, M., Allasia, C., Bonnier, P., et al. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.015 · Cited by 156
Gene amplification in gastric and esophageal adenocarcinomas.
Houldsworth, J., Cordon‐Cardo, C., Ladanyi, M., Kelsen, D. P., & Chaganti, R. S. K. (1990) · PubMed · Cited by 156
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
Puri, N., Ahmed, S., Janamanchi, V., Tretiakova, M., Zumba, O., Krausz, T. N., Jagadeeswaran, R., & Salgia, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0776 · Cited by 155
Kim, K. J., Wang, L., Su, Y.-C., Gillespie, G. Y., Salhotra, A., Lal, B., & Laterra, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1793 · Cited by 150
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists
Michieli, P., Basilico, C., Pennacchietti, S., Maffé, A., Tamagnone, L., Giordano, S., Bardelli, A., & Comoglio, P. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202899 · Cited by 140
Graveel, C. R., Su, Y., Koeman, J. M., Wang, L.-M., Tessarollo, L., Fiscella, M., Birchmeier, C., Swiatek, P. J., Bronson, R. T., & Woude, G. V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407651101 · Cited by 128
Lorenzato, A., Olivero, M., Patanè, S., Rosso, E., OLIARO, A., Comoglio, P. M., & Renzo, M. F. D. (2002) · PubMed · Cited by 124
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicėnas, S., Szczęsna, A., Juhász, É., Gonzalez, E., Molinier, O., Klingelschmitt, G., & Giaccone, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8001 · Cited by 124
Ferracini, R., Olivero, M., Renzo, M. F. D., Martano, M., Giovanni, C. D., Nanni, P., Basso, G., Scotlandi, K., Lollini, P., & Comoglio, P. M. (1996) · PubMed · Cited by 122
MET as a target for treatment of chest tumors
Cipriani, N. A., Abidoye, O. O., Vokes, E. E., & Salgia, R. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.011 · Cited by 121
Tong, C. Y., Hui, A. B., Yin, X.-L., Pang, J. C., Zhu, X.-L., Poon, W. S., & Ng, H. (2004) · Journal of Neurosurgery Pediatrics · doi:10.3171/ped.2004.100.2.0187 · Cited by 116
Hussain, M., Smith, M. R., Sweeney, C. J., Corn, P. G., Elfiky, A. A., Gordon, M. S., Haas, N. B., Harzstark, A. L., Kurzrock, R., Lara, P. N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4516 · Cited by 111
Gómez-Quiroz, L. E., Factor, V. M., Kaposi-Novák, P., Coulouarn, C., Conner, E. A., & Thorgeirsson, S. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707733200 · Cited by 108
Ocal, I. T., Dolled-Filhart, M. P., D'Aquila, T. G., et al. (2003) · Cancer · doi:10.1002/cncr.11335 · Cited by 103
Takanami, I., Tanana, F., Hashizume, T., et al. (2009) · Oncology · doi:10.1159/000227594 · Cited by 100
Bauer, T. W., Somcio, R., Fan, F., Liu, W., Johnson, M., Lesslie, D. P., Evans, D. B., Gallick, G. E., & Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0175 · Cited by 99
An uncleavable form of pro–scatter factor suppresses tumor growth and dissemination in mice
Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S., Risio, M., Naldini, L., Comoglio, P. M., & Michieli, P. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22235 · Cited by 97
Yamazaki, S., Skaptason, J., Romero, D., Lee, J. H., Zou, H. Y., Christensen, J. G., Koup, J. R., Smith, B. J., & Koudriakova, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019711 · Cited by 94
Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?
Wong, A. S. T., Pelech, S., Woo, M. M. M., Yim, G., Rosen, B. P., Ehlen, T. G., Leung, P. C. K., & Auersperg, N. (2001) · Oncogene · doi:10.1038/sj.onc.1204253 · Cited by 77
Clinical Significance of c-met Oncogene Alterations in Human Colorectal Cancer
Umeki, K., Shiota, G., & Kawasaki, H. (1999) · Oncology · doi:10.1159/000011985 · Cited by 64
Wakelee, H. A., Gettinger, S. N., Engelman, J. A., Janne, P. A., West, H., Subramaniam, D. S., Leach, J. W., Wax, M., Yaron, Y., & Lara, P. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3017 · Cited by 63
C-MET as a new therapeutic target for the development of novel anticancer drugs
Cañadas, I., Rojo, F., Arumí-Uría, M., Rovira, A., Albanell, J., & Arriola, E. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0501-0 · Cited by 56
NK4 gene therapy targeting HGF-Met and angiogenesis
Matsumoto, K. (2007) · Frontiers in bioscience · doi:10.2741/2813 · Cited by 42
Eng, C., Cutsem, E. V., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E. P., Давиденко, І., Oliner, K. S., Chen, L., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3500 · Cited by 37
Tan, E. H., Park, K., Lim, W. T., Ahn, M., Ng, Q. S., Ahn, J. S., Tan, D. S., Sun, J., Jac, J., Han, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7571 · Cited by 36
Jones, S. F., Cohen, R. B., Bendell, J. C., Denlinger, C. S., Harvey, R. D., Parasuraman, S., Chi, X., Scholz, C. R., Wyant, T., & Kauh, J. S. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3081 · Cited by 27
Effective Use of Thalidomide in the Treatment of Recurrent Metastatic Chordoma
Chay, W. Y., Teo, M., Sittampalam, K., & Toh, H. C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2139 · Cited by 26
Fan, S., Meng, Q., Laterra, J., & Rosen, E. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210271 · Cited by 25
Role of PYK2 in the development of obesity and insulin resistance
Yu, Y., Ross, S. A., Halseth, A. E., Hollenbach, P. W., Hill, R. J., Gulve, E. A., & Bond, B. R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.198 · Cited by 24
Torti, D., Sassi, F. P., Galimi, F., Gastaldi, S., Perera, T. P. S., Comoglio, P. M., Trusolino, L., & Bertotti, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26137 · Cited by 22
Zucali, P. A., Santoro, A., Rodriguez-Lope, C., Simonelli, M., Camacho, L. H., Senzer, N. N., Bolondi, L., Lamar, M. E., Abbadessa, G., & Schwartz, B. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4137 · Cited by 17
Oh, D. A., Han, S., Kim, T. M., Lee, S., Kim, T., Heo, D. S., & Bang, Y. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13056 · Cited by 8
Cited by
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Mellman, I., & Yarden, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016949 · Cited by 394
Metadata
- Authors
- Blumenschein, G. R., Mills, G. B., & Gonzalez-Angulo, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-09-10
- Volume
- 30
- Issue
- 26
- Pages
- 3287-3296
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2062110561
- Cited by
- 273
- References
- 90
- FWCI
- 16.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.